We are a community of blood cancer patients, survivors and caregivers. We’re here to support you, give you trusted information and resources, and help you feel connected. No one should have to face a blood cancer diagnosis alone.
The U.S. Food and Drug Administration (FDA) approved loncastuximab tesirine-lpyl (ZYNLONTA) to treat adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more earlier treatments with systemic therapy including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. The FDA approval is based on a Phase 2 study that enrolled 145 patients with R/R DLBCL or high-grade lymphoma including patients with difficult-to-treat disease. Results from the tri...
Our “Meet the Researcher” series on The LLS Blog shares what our outstanding LLS-funded researchers are working on, the incredible impact they’re making in the fight against blood cancers, and what inspires their efforts to find better treatments and cures. In honor of Asian American and Pacific Islander Heritage Month in May, LLS is highlighting the stories of volunteers, healthcare professionals, researchers, patients, survivors, and advocates from across our community. Recent...
Our “Meet the Researcher” series shares what outstanding LLS-affiliated researchers are working on, the incredible impact they are making in the fight against blood cancer, and what inspires their efforts to find better treatments and cures. In this Q&A, we are highlighting Dr. Christopher R. Flowers, MD, chair of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center and LLS National Board Member. Later this week, Dr. Flowers will be speaking on a timely panel a...
LLS Community is getting an upgrade! We have appreciated LLS Community member feedback as we make improvements to help you navigate the community more easily while receiving information and support. These updates will be visible to you in June. What You Will See -The layout will look familiar but is now easier to read, with tabs to access various parts of the Community at the top, guidance and contact information at the bottom and your feed in between -The page tabs will be the sam...
Help us advocate for affordable, quality health coverage for cancer patients! On May 19 we'll show you how to message your members of Congress and urge them to stand up for patients. Text LLSACTION to 69866 or visit http://bit.ly/LLS-Sign-Up Forty-two percent of cancer patients deplete their life savings within two years of their diagnosis. It's a horrifying figure that reveals how far we still have to come to ensure all patients have access to quality, affordable treatments. E...
Collaborations with Mayo Clinic, Vanderbilt University Medical Center and Weill Cornell Medicine will Increase Representation of Geographically, Ethnically and Economically Underserved Communities in Clinical Trials RYE BROOK, N.Y., May 6, 2021 – The Leukemia & Lymphoma Society (LLS) announced today the launch of the IMPACT (Influential Medicine Providing Access to Clinical Trials) research grants to increase enrollment of individuals from underrepresented communities in clinical tri...
The first big oncology meeting of the year, American Association for Cancer Research (AACR) kicked off with week one of the meeting held from April 10-15, 2021. Key topics from the virtual meeting include concerns for blood cancer patients such as building COVID-19 vaccine confidence and addressing cancer health disparities, as well as research into ways to improve CAR T-cell immunotherapy. Read on for a closer look at the top news from AACR: Building Vaccine Confidence I was invited...
Living Well with Leukemia, Lymphoma, and Myeloma: An Integrative Workshop for Patients and Caregivers A Virtual Education Program (Desert) May 1, 2021 10:00am – 12:00pm (PT) https://www.lls.org/events/living-well-with-leukemia-lymphoma-and-myeloma-az Young Adult Cancer Survivorship A Virtual Education Program (New England) May 4, 2021 6:00pm – 8:00pm (ET) https://www.lls.org/events/YA-Cancer-Survivorship Blood Cancer Related Fatigue: Developing Your Own Personalized Care Pla...
The Leukemia & Lymphoma Society (LLS) has heard from blood cancer patients and caregivers who are concerned about new research suggesting that mRNA-based COVID-19 vaccines may offer less protection for people with certain blood cancers. The findings from the new research confirm what LLS and other experts expected: that certain types of blood cancer and blood cancer treatments could affect vaccine response. Additional research is underway including collection of real-world data in the ...
Background and Purpose Because of the health emergency created by the COVID-19 virus, three COVID-19 vaccinations have been authorized by the U.S. FDA for Emergency Use Administration (EUA). The vaccine clinical trials were streamlined and essentially excluded people with a current or past diagnosis of cancer. Therefore, how people with blood cancer respond to the COVID-19 vaccinations is unknown. The Leukemia & Lymphoma Society National Patient Registry, created in honor of Michael...
